(Q53657170)
Statements
Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing. (English)
Koon HB
Severy P
Hagg DS
Butler K
Hill T
Jones AG
Waldmann TA
Junghans RP
13 September 2005
30
2
190-203